MCID: CHR285
MIFTS: 63

Chronic Myelomonocytic Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Genetic diseases, Immune diseases

Aliases & Classifications for Chronic Myelomonocytic Leukemia

MalaCards integrated aliases for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia 37 12 72 49 55 28
Leukemia, Myelomonocytic, Chronic 49 69
Myelomonocytic Leukemia, Chronic 13
Leukemia Myelomonocytic Chronic 51
Cmml 55

Characteristics:

Orphanet epidemiological data:

55
chronic myelomonocytic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0080188
NCIt 46 C3178
Orphanet 55 ORPHA98823
MESH via Orphanet 42 D015477
UMLS via Orphanet 70 C0023480
ICD10 via Orphanet 33 C93.1
ICD10 32 C93.1
UMLS 69 C0023480

Summaries for Chronic Myelomonocytic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

MalaCards based summary : Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to myelodysplastic myeloproliferative cancer and juvenile myelomonocytic leukemia, and has symptoms including night sweats, fever and fatigue. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are cellular and growth/size/body region

NIH Rare Diseases : 49 This condition doesn't have a summary yet. Please see our page(s) on Myelodysplastic/myeloproliferative disease.

Wikipedia : 72 Chronic myelomonocytic leukaemia (CMML) is a type of leukaemia, which are cancers of the blood-forming... more...

Related Diseases for Chronic Myelomonocytic Leukemia

Diseases in the Chronic Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic myeloproliferative cancer 31.2 ASXL1 JAK2 SETBP1 TET2
2 juvenile myelomonocytic leukemia 31.0 DNMT3A FLT3 JAK2 PDGFRB RUNX1 SETBP1
3 chronic neutrophilic leukemia 30.5 ASXL1 SETBP1
4 leukemia 30.0 ETV6 FLT3 JAK2 KIT RUNX1
5 refractory anemia with excess blasts 30.0 ASXL1 SETBP1 TET2
6 myeloid leukemia 29.7 ETV6 FLT3 KIT RUNX1 TET2
7 refractory anemia 29.7 ASXL1 JAK2 RUNX1 TET2
8 splenomegaly 29.7 JAK2 SETBP1
9 mast cell disease 29.6 KIT PDGFRB TET2
10 atypical chronic myeloid leukemia 29.5 ASXL1 JAK2 RUNX1 SETBP1
11 myeloproliferative neoplasm 29.5 ETV6 JAK2 PDGFRB TET2
12 systemic mastocytosis 29.3 JAK2 KIT PDGFRB TET2
13 myelodysplastic syndrome 29.3 ASXL1 ETV6 FLT3 JAK2 KIT PDGFRB
14 myeloid sarcoma 29.2 FLT3 KIT
15 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 29.2 ETV6 FLT3 KIT RUNX1
16 lymphoblastic leukemia 29.0 ETV6 FLT3 JAK2 RUNX1
17 aplastic anemia 28.9 ASXL1 FLT3 TET2
18 essential thrombocythemia 28.8 ASXL1 EZH2 JAK2 TET2
19 acute leukemia 28.5 ETV6 FLT3 JAK2 KIT RUNX1
20 polycythemia vera 28.4 ASXL1 JAK2 KIT PDGFRB TET2
21 leukemia, chronic myeloid 27.9 ETV6 FLT3 JAK2 KIT PDGFRB RUNX1
22 myelofibrosis 27.8 ASXL1 EZH2 FLT3 JAK2 KIT PDGFRB
23 leukemia, acute myeloid 27.2 ASXL1 DNMT3A ETV6 EZH2 FLT3 JAK2
24 pdgfrb-associated chronic eosinophilic leukemia 11.8
25 platelet disorder, familial, with associated myeloid malignancy 10.3 ETV6 RUNX1
26 primary hypereosinophilic syndrome 10.3 ETV6 PDGFRB
27 myeloproliferative disorder, chronic, with eosinophilia 10.3 ETV6 PDGFRB
28 lymphoid leukemia 10.2 ETV6 RUNX1
29 sm-ahnmd 10.2 ASXL1 KIT
30 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
31 thrombocytopenia 10.1
32 mn1 10.1 ETV6 FLT3
33 leukemia, chronic lymphocytic 2 10.1
34 leukemia, chronic lymphocytic 10.1
35 hematopoietic stem cell transplantation 10.1
36 leukemia, b-cell, chronic 10.1
37 desmoid tumor 10.1 KIT PDGFRB
38 congenital mesoblastic nephroma 10.1 ETV6 KIT
39 hypereosinophilic syndrome, idiopathic 10.1 KIT PDGFRB
40 myeloma, multiple 10.0
41 lymphoma 10.0
42 sarcoma 10.0
43 heart sarcoma 10.0 KIT PDGFRB
44 acute myeloblastic leukemia with maturation 10.0 FLT3 KIT
45 blood group, i system 10.0
46 graft-versus-host disease 10.0
47 purpura 10.0
48 histiocytosis 10.0
49 vasculitis 10.0
50 aleukemic leukemia cutis 9.9 FLT3 RUNX1

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:



Diseases related to Chronic Myelomonocytic Leukemia

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

UMLS symptoms related to Chronic Myelomonocytic Leukemia:


night sweats, fever, fatigue

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 KIT JAK2 PDGFRB KDM6A HIP1 ASXL1
2 growth/size/body region MP:0005378 10.27 KIT JAK2 PDGFRB KDM6A HIP1 RUNX1
3 hematopoietic system MP:0005397 10.26 KIT JAK2 PDGFRB KDM6A HIP1 ASXL1
4 endocrine/exocrine gland MP:0005379 10.25 JAK2 PDGFRB KIT ASXL1 EZH2 TET2
5 homeostasis/metabolism MP:0005376 10.23 KIT JAK2 PDGFRB KDM6A HIP1 ETV6
6 immune system MP:0005387 10.21 KIT JAK2 PDGFRB KDM6A HIP1 ASXL1
7 mortality/aging MP:0010768 10.18 KIT JAK2 PDGFRB KDM6A HIP1 ASXL1
8 embryo MP:0005380 10.13 KIT JAK2 KDM6A ETV6 RUNX1 EZH2
9 neoplasm MP:0002006 9.91 JAK2 KIT ASXL1 EZH2 TET2 FLT3
10 liver/biliary system MP:0005370 9.88 HIP1 KIT JAK2 RUNX1 ASXL1 TET2
11 muscle MP:0005369 9.8 HIP1 KIT KDM6A EZH2 DNMT3A PDGFRB
12 no phenotypic analysis MP:0003012 9.76 KIT KDM6A ETV6 RUNX1 EZH2 TET2
13 normal MP:0002873 9.61 KIT JAK2 PDGFRB KDM6A HIP1 ETV6
14 skeleton MP:0005390 9.28 HIP1 KIT JAK2 PDGFRB KDM6A RUNX1

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 404)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
6
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
7
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
8
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
11
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
12
Ofloxacin Approved Phase 3 82419-36-1 4583
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Idarubicin Approved Phase 3,Phase 1,Phase 2 58957-92-9 42890
15
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
16
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
17
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
18
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 83-43-2 6741
19
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 50-24-8 5755
20
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
21
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
22
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
23
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
24
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
25
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
26
Aldesleukin Approved Phase 3,Phase 1,Phase 2 110942-02-4, 85898-30-2
27
Asparaginase Approved, Investigational Phase 3 9015-68-3
28
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
29
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
30
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 657311 5754
31
Thioguanine Approved Phase 3 154-42-7 2723601
32 Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
33
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
34
Ephedrine Approved Phase 3 299-42-3 9294
35
Pseudoephedrine Approved Phase 3 90-82-4 7028
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
37
Dalteparin Approved Phase 3 9005-49-6
38
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
39
Ondansetron Approved Phase 3,Phase 2,Phase 1 99614-02-5 4595
40
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
41
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
42
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
43
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
44
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
45
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
46
Morphine Approved, Investigational Phase 3 57-27-2 5288826
47
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
48
Iron Approved Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
49
Allopurinol Approved Phase 3,Phase 2,Phase 1 315-30-0 2094
50
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 467)

# Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
3 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
7 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
8 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
13 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
14 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
15 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 Decitabine Versus Supportive Care in Adults With Advanced-stage MDS Completed NCT00043381 Phase 3 decitabine (5-aza-2'deoxycytidine)
17 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
18 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
19 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
20 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
21 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
24 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
25 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
31 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
32 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
33 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
34 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
35 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Recruiting NCT02907359 Phase 3 Guadecitabine
36 Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
37 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
38 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Active, not recruiting NCT01757535 Phase 3 300 mg Oral Azacitidine;Placebo
39 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
40 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
41 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
42 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
43 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
44 Phase 3 Study of ASTX727 vs IV Decitabine in MDS and CMML Not yet recruiting NCT03306264 Phase 3 ASTX727;Dacogen
45 Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Terminated NCT00109538 Phase 3 Lonafarnib
46 Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
47 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
48 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
49 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
50 Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:
Hemacord
Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244

Genetic Tests for Chronic Myelomonocytic Leukemia

Genetic tests related to Chronic Myelomonocytic Leukemia:

# Genetic test Affiliating Genes
1 Chronic Myelomonocytic Leukemia 28

Anatomical Context for Chronic Myelomonocytic Leukemia

MalaCards organs/tissues related to Chronic Myelomonocytic Leukemia:

38
Myeloid, Bone, Bone Marrow, Monocytes, T Cells, Kidney, Liver

Publications for Chronic Myelomonocytic Leukemia

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 548)
# Title Authors Year
1
A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN<sup>TM</sup>analyzers in routine laboratory practice. ( 29310473 )
2018
2
KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation. ( 29151134 )
2018
3
Leukemia cutis in a patient with chronic myelomonocytic leukemia. ( 29288601 )
2018
4
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. ( 29358618 )
2018
5
Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. ( 29368535 )
2018
6
Chronic myelomonocytic leukemia with central nervous system involvement. ( 29322838 )
2018
7
Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia. ( 29227812 )
2018
8
DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. ( 29160764 )
2018
9
Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine. ( 29170809 )
2018
10
Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia. ( 28842140 )
2017
11
Current management of patients with chronic myelomonocytic leukemia. ( 27849645 )
2017
12
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. ( 28548124 )
2017
13
Posttransplantation relapse of pediatric chronic myelomonocytic leukemia cured using donor lymphocyte infusion. ( 28895279 )
2017
14
Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan. ( 29196081 )
2017
15
Adult chronic myelomonocytic leukemia with trisomy 11: a case report. ( 29270065 )
2017
16
Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. ( 28593791 )
2017
17
High sensitivity of the Hematoflowa8c solution for chronic myelomonocytic leukemia screening. ( 29108126 )
2017
18
Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. ( 28707414 )
2017
19
How I treat chronic myelomonocytic leukemia. ( 28572287 )
2017
20
Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. ( 29192651 )
2017
21
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article. ( 29069007 )
2017
22
Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. ( 28731458 )
2017
23
A Rare Case of Paraneoplastic Aortitis Associated with Chronic Myelomonocytic Leukemia. ( 28630775 )
2017
24
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. ( 29121539 )
2017
25
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. ( 28498370 )
2017
26
Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia. ( 28209919 )
2017
27
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. ( 28853315 )
2017
28
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. ( 28607470 )
2017
29
Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. ( 28702776 )
2017
30
Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. ( 28442268 )
2017
31
Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia. ( 28912296 )
2017
32
Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. ( 29296739 )
2017
33
Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. ( 29032731 )
2017
34
Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. ( 29262560 )
2017
35
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. ( 27733013 )
2017
36
Models of Prognostication in Chronic Myelomonocytic Leukemia. ( 29064026 )
2017
37
Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia. ( 29122774 )
2017
38
Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia. ( 28522578 )
2017
39
Genomic determinants of chronic myelomonocytic leukemia. ( 28555081 )
2017
40
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. ( 28905323 )
2017
41
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. ( 28885734 )
2017
42
Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis. ( 28158286 )
2017
43
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. ( 28621841 )
2017
44
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. ( 28486043 )
2017
45
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. ( 27521328 )
2016
46
Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors. ( 27585952 )
2016
47
Age-related mutations and chronic myelomonocytic leukemia. ( 26648538 )
2016
48
Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. ( 27337291 )
2016
49
Chronic myelomonocytic leukemia mimicking hematologic systemic lupus erythematosus. ( 27365372 )
2016
50
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. ( 27385790 )
2016

Variations for Chronic Myelomonocytic Leukemia

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160282 22 11800000 24300000 Translocation Chronic myelomonocytic leukemia
2 228217 7 75001344 75206215 Translate HIP1 Chronic myelomonocytic leukemia
3 247204 9 129300000 140273252 Translocation Chronic myelomonocytic leukemia

Expression for Chronic Myelomonocytic Leukemia

Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.

Pathways for Chronic Myelomonocytic Leukemia

GO Terms for Chronic Myelomonocytic Leukemia

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.36 ASXL1 DNMT3A ETV6 EZH2 FLT3 HIP1

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 FLT3 JAK2 KIT PDGFRB
2 regulation of gene expression GO:0010468 9.77 DNMT3A EZH2 KDM6A
3 positive regulation of cell migration GO:0030335 9.77 JAK2 KIT PDGFRB
4 positive regulation of protein kinase B signaling GO:0051897 9.73 HIP1 KIT PDGFRB
5 cytokine-mediated signaling pathway GO:0019221 9.72 FLT3 JAK2 KIT
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.71 FLT3 KIT PDGFRB
7 protein autophosphorylation GO:0046777 9.71 FLT3 JAK2 KIT PDGFRB
8 response to estradiol GO:0032355 9.67 DNMT3A EZH2 PDGFRB
9 peptidyl-tyrosine phosphorylation GO:0018108 9.67 FLT3 JAK2 KIT PDGFRB
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 FLT3 JAK2 KIT
11 platelet-derived growth factor receptor signaling pathway GO:0048008 9.58 JAK2 PDGFRB
12 DNA methylation GO:0006306 9.57 DNMT3A EZH2
13 hemopoiesis GO:0030097 9.56 ASXL1 FLT3 KIT RUNX1
14 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.52 JAK2 PDGFRB
15 hematopoietic stem cell proliferation GO:0071425 9.51 ETV6 RUNX1
16 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.5 FLT3 KIT PDGFRB
17 positive regulation of phospholipase C activity GO:0010863 9.48 KIT PDGFRB
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.46 FLT3 JAK2 KIT PDGFRB
19 myeloid progenitor cell differentiation GO:0002318 9.43 FLT3 KIT
20 positive regulation of MAP kinase activity GO:0043406 9.26 EZH2 FLT3 KIT PDGFRB
21 covalent chromatin modification GO:0016569 9.1 ASXL1 DNMT3A EZH2 JAK2 KDM6A TET2

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.87 ASXL1 DNMT3A ETV6 EZH2 RUNX1 SETBP1
2 protein kinase activity GO:0004672 9.71 FLT3 JAK2 KIT PDGFRB
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 JAK2 KIT PDGFRB
4 phosphatidylinositol 3-kinase binding GO:0043548 9.26 JAK2 PDGFRB
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 FLT3 KIT PDGFRB
6 protein tyrosine kinase activity GO:0004713 8.92 FLT3 JAK2 KIT PDGFRB
7 protein binding GO:0005515 10.15 ASXL1 DNMT3A ETV6 EZH2 FLT3 HIP1

Sources for Chronic Myelomonocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....